Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

OCJOY Debuts at IFA 2026: Bringing Clinic-Grade Oral Care Home

August 27, 2026

Cambridge Atomworks opens new facility and laboratory at Granta Park

August 27, 2026

TekniPlex Healthcare Brings Materials Science- Led Medical Device Solutions to Southeast Asia at Medical Fair 2026

August 27, 2026

Kraken Robotics Reports Q2 2026 Financial Results

August 27, 2026

Blossom Gold Reports Initial Metallurgical Results and Engagement of Metallurgical Advisor for the Rosebud Open-Pit, Heap-Leach Project

August 27, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Press Release

BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

By News RoomMarch 24, 20262 Mins Read
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Share
Facebook Twitter LinkedIn Pinterest Email

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Shares of Beta Bionics, Inc. (NASDAQ: BBNX) plunged approximately 37% on January 09, 2026 after the company announced that it expects fewer patient starts in the fourth quarter than estimated by analysts. 

To learn more about the Beta Bionics investigation, go to www.faruqilaw.com/BBNX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

OCJOY Debuts at IFA 2026: Bringing Clinic-Grade Oral Care Home

Cambridge Atomworks opens new facility and laboratory at Granta Park

TekniPlex Healthcare Brings Materials Science- Led Medical Device Solutions to Southeast Asia at Medical Fair 2026

Kraken Robotics Reports Q2 2026 Financial Results

Blossom Gold Reports Initial Metallurgical Results and Engagement of Metallurgical Advisor for the Rosebud Open-Pit, Heap-Leach Project

MEXC Launches SHEIN Subscription with $1M Quota as Inaugural IPO Express Event

Hyperliquid News: CopyLiquid Market, The First Copy Trading Platform on Hyperliquid Opens $COPY Presale to Early Investors

Rupert Grint to Reprise Film Role of “Ron Weasley” in Harry Potter and the Cursed Child on Broadway in New York City

HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System

Editors Picks

Cambridge Atomworks opens new facility and laboratory at Granta Park

August 27, 2026

TekniPlex Healthcare Brings Materials Science- Led Medical Device Solutions to Southeast Asia at Medical Fair 2026

August 27, 2026

Kraken Robotics Reports Q2 2026 Financial Results

August 27, 2026

Blossom Gold Reports Initial Metallurgical Results and Engagement of Metallurgical Advisor for the Rosebud Open-Pit, Heap-Leach Project

August 27, 2026

Latest News

MEXC Launches SHEIN Subscription with $1M Quota as Inaugural IPO Express Event

August 27, 2026

Hyperliquid News: CopyLiquid Market, The First Copy Trading Platform on Hyperliquid Opens $COPY Presale to Early Investors

August 27, 2026

Rupert Grint to Reprise Film Role of “Ron Weasley” in Harry Potter and the Cursed Child on Broadway in New York City

August 27, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version